Merck’s remigromig Meets Primary Endpoint in Diabetic Macular Edema Trial

Key Facts

In a move reflecting the ongoing advancements in the healthcare sector to address diabetes complications, Merck has announced positive clinical trial results. According to reports, the investigational drug remigromig met its primary endpoint in a clinical trial targeting diabetic macular edema (DME). These results mark a significant step in demonstrating the drug's efficacy in treating a common vision-threatening complication of diabetes.

This development comes as major pharmaceutical companies look to strengthen their biotechnology portfolios. Per market data, MRK stock closed at $148.08 on September 23, 2026, having reached a day high of $152.01 and a low of $146.89. This performance highlights the company's relative stability within the competitive healthcare landscape.

Investors are currently monitoring price levels based on recent trading ranges, with MRK at $148.08 (close September 23, 2026). Looking at the economic calendar, there are no major upcoming catalysts specifically for the pharmaceutical sector in the next seven days, leaving the focus on subsequent clinical trial milestones as the primary driver.